Latest Fda Approved Drugs Information Systems

HYATTSVILLE, MD — Only about 48% of adults with hypertension had it under control during 2015–2016, according to data released today by the National Center for Health Statistics (NCHS) at the Centers for Disease Control and Prevention (CDC) [ 1 ] . "This finding that just under half of adults with hypertension have their BP under control is consistent with estimates since 2010," first author Cheryl Fryar, NCHS Division of Health and Nutrition Examination Surveys, told  theheart.org | Medscape Cardiology . "However, this statistic shows that we have yet to meet the Healthy People 2020 goal of 61.2% for hypertension control." The report also shows that hypertension is more prevalent in US non-Hispanic black adults than in other race/ethnic-origin groups. Hypertension raises the risk of cardiovascular disease and "remains an important public-health challenge" in the US. Effective control of elevated blood pressure has been shown to reduce stroke, MI,

SAN DIEGO — Patients with a history of head injury show significant increases in amyloid deposition in key parts of the brain, including the frontal cortex, a finding that further supports evidence linking head injury with dementia later in life. "Our study found associations between prior head injury and increased amyloid deposition both globally and within the frontal cortex, including orbitofrontal, prefrontal, and superior frontal cortices," Andrea Schneider, MD, PhD, from Johns Hopkins University, Baltimore, Maryland, told  Medscape Medical News. "Our findings suggest that the frontal cortex may be particularly susceptible to the damaging effects of head injury." The findings were presented here at the ANA 2017: 48th Annual Meeting of the American Neurological Association. Head injury has been linked to dementia in previous epidemiologic studies, and while the mechanisms are not well understood, amyloid and tau depositions are speculated to be likel

Transfusions from females who have been pregnant to males, especially those younger than 50 years, may be associated with increased risk for all-cause mortality, compared with such transfusions to females or with transfusions from women who have never been pregnant to recipients of either sex, according to a study  published online  on October 17 in  JAMA. Since 2011, several studies have suggested that blood transfusions from women are riskier for recipients than are transfusions from men, and that that risk is greatest from women who have been pregnant. The most common cause of transfusion-related mortality, acute lung injury, is associated with use of plasma-rich products, suggesting an antibody-mediated immune response. To further examine these associations, Camila Caram-Deelder, a PhD student in the Department of Transfusion Medicine at Sanquin Research, Leiden, the Netherlands, and coworkers analyzed the association between red blood cell transfusion from female blood donor

Palliative care and pain relief continue to remain neglected elements of global healthcare, according to a major new article  published online  October 13 in the  Lancet. The report is the first to provide a worldwide estimate of the extent of serious suffering related to illness and injury and the resultant need for palliative care and pain relief. More than 25.5 million people die every year without adequate relief for serious physical and psychological suffering ― nearly half of all deaths reported in 2015. The report also states that an additional 35.5 million people require pain relief for reasons other than end-of-life care. The vast majority of these patients (>80%) live in low- and middle-income countries, where access to immediate-release morphine, an essential and inexpensive drug to relieve pain, is severely lacking. Writing in a  linked commentary , Richard Horton, MD, editor-in-chief of the  Lancet , notes, "Death and disability are important metrics fo

Smoking, pulmonary hypertension, and a decline in lung function are associated with an increased risk of death in people with chronic obstructive pulmonary disease (COPD). Now researchers in Spain have added another potential risk factor: the presence and severity of bronchiectasis. Compared with unaffected patients with COPD, patients with bronchiectasis had more than double the risk of dying than those without, according to a prospective, observational study published online February 8 in the  American Journal of Respiratory and Critical Care Medicine . Miguel Angel Martínez-García, MD, from the Pneumology Service at the University and Polytechnic La Fe Hospital in Valencia, Spain, and colleagues assessed 201 participants with moderate to severe COPD from a consecutive series of outpatients diagnosed at 1 of 2 specialty clinics in Spain. The mean age of participants was 70 years, and 91% were men. A majority (77%) featured radiologic signs of emphysema. Patients were diagnosed

Smoking, pulmonary hypertension, and a decline in lung function are associated with an increased risk of death in people with chronic obstructive pulmonary disease (COPD). Now researchers in Spain have added another potential risk factor: the presence and severity of bronchiectasis. Compared with unaffected patients with COPD, patients with bronchiectasis had more than double the risk of dying than those without, according to a prospective, observational study published online February 8 in the  American Journal of Respiratory and Critical Care Medicine . Miguel Angel Martínez-García, MD, from the Pneumology Service at the University and Polytechnic La Fe Hospital in Valencia, Spain, and colleagues assessed 201 participants with moderate to severe COPD from a consecutive series of outpatients diagnosed at 1 of 2 specialty clinics in Spain. The mean age of participants was 70 years, and 91% were men. A majority (77%) featured radiologic signs of emphysema. Patients were diagnosed

The US Food and Drug Administration (FDA) today issued a proposal designed to assist companies focused on the development of new treatments for patients in the early stages of Alzheimer's disease (AD). "The scientific community and the FDA believe that it is critical to identify and study patients with very early Alzheimer's disease before there is too much irreversible injury to the brain," Russell Katz, MD, director of the Division of Neurology Products in the FDA's Center for Drug Evaluation and Research, said in a statement announcing the draft proposal. "It is in this population that most researchers believe that new drugs have the best chance of providing meaningful benefit to patients," he added. The  guidance document  outlines the FDA's current thinking about how best to identify and select patients with early AD, or those who are at risk of developing the disease, for enrollment in clinical trials, the FDA explains. The proposal ad